Management Team

Eric G LeVeen MD FACS is a board-certified surgeon and a fellow of the American College 
of Surgeons. He has patented devices in the medical and surgical fields that have become commercial products in the medical device industry. Among the commercialized devices, the peritoneal venous shunt for ascites, marketed by Becton Dickenson, the LeVeen screw syringe angioplasty device marketed by Boston Scientific and the percutaneous radiofrequency ablation device for liver metastases. During his decades of medical practice, Dr. LeVeen has had a lifetime interest in wound healing, publishing many scientific articles. He has patented the iodination of polyurethane and is a co-author of ‘The Mythology of Povidone Iodine and the Development of Self-Sterilizing Plastics’. His current interest in managing wounds and burn injuries has led to his development of an iodinated hydrogel wound dressing that is both comfortable and bactericidal while non injurious to mammalian tissue. Unlike nano particle silver there is no bacterial resistance to iodine.

Mr. Craig Lambert holds a BSEE from the University of California at Davis and an MSEE from San Jose State University, specializing in semiconductor physics and processing. He started his career as a product engineer at National Semiconductor, later moving to integrated circuit design. Over the years, Craig worked at various semiconductor and systems companies, including a startup and AT&T's Bell Labs in the mass storage group. He has developed products ranging from simple voltage references to complex power management ICs, with a focus on precision small-signal circuits, resulting in eight patents. His innovations are used in diverse medical devices, avionics, and consumer electronics applications. His interests include integrating emerging sensors into systems for monitoring subtle and rapid parameter changes, with a primary focus on analog IC design alongside digital and mixed-signal circuits. Craig is leading the design, fabrication, and integration of the biosensors system for the iodinated wound dressing.

Mr. Andrew Lam, BS, has over 30 years of experience in pharmaceutical product development and has contributed to the NDA registration and regulatory approvals of multiple products in the US, EU, Japan, and China. Prior to Tranquis, Andrew held senior management positions at Espero, Armetheon, Altheos, Exelixis and ALZA, a Johnson and Johnson company. He advanced discovery compounds in late-stage optimization to IND clinical development and directed chemical development, product scale-up, registration, and global product launch. Andrew was the recipient of the Johnson Medical, the highest scientific award at J&J, for the development of Concerta®. Andrew earned his BS degree in Chemical Engineering with high honors from the University of California, Davis.

With over two decades of experience in the healthcare industry, Mr. Paul Howe has led commercial teams in public and private life science companies. Most recently, Paul is the Chief Commercial Officer of Protega Pharma, responsible for all commercial operations. Prior to Protega Pharma, Paul served as Senior Vice President of Sales and Commercial Strategy at AcelRx, a specialty pharmaceutical company. Paul also held senior management positions at Glaxo Smith Kline, XenoPort, and Reliant Pharmaceuticals. He started his career at Sanofi, encompassing roles at Aventis and Hoechst Marion Roussel. Additionally, Paul serves on the Board of Maximus Health.